SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series.
Mattia ZampieriAlessia ArgiròMarco AllinoviFederico PerfettoFrancesco CappelliPublished in: Internal and emergency medicine (2022)